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Abstract
Purpose CT attenuation of ischemic brain reduces with time after stroke onset.We aimed to quantify this relationship and test the
feasibility and accuracy of estimating stroke onset time using only CT attenuation of visible ischemic lesions, the CT-Clock Tool.
Methods We selected CT scans with ischemic lesions representing a range of stroke-onset-to-scan times (elapsed time) from a
well-defined stroke trial. We measured the attenuation of ischemic lesions and contralateral normal brain to derive attenuation
ratio. We assigned scans to development (75%) or test (25%) datasets. We plotted the relationship between attenuation ratio and
elapsed time in the development dataset and derived a best-fit curve. We calculated estimated time in the test dataset using only
the attenuation ratio curve. We compared estimated time to elapsed time and derived absolute error for estimated time. We
assessed area under the receiver operating characteristic (AUROC) curve for identifying scans ≤ 4.5 h elapsed time.
Results We included 342 scans from 200 patients (41% male, median age 83 years). Elapsed time range: 22 min to 36 days.
Estimation errors were least at early elapsed times (r = 0.82, p < 0.0001): median absolute error was 23, 106, 1030 and 1933 min
for scans acquired ≤ 3, > 3–9, > 9–30 and > 30 h from stroke onset, respectively. AUROC was high at 0.955.
Conclusions It is feasible to accurately estimate stroke onset time using simple attenuation measures of ischemic brain. Our
method was most accurate 0–9 h from onset and may be useful for treatment eligibility assessment, especially where imaging
resources are limited.
Keywords Stroke . Ischemia . CT . Attenuation
Introduction
In the first hours and days following the onset of an ischemic
stroke, the CT attenuation of affected brain reduces with time.
Within a few hours of symptom onset, ischemic lesions are
often not visible to the naked eye. By 3–6 h, subtle changes
such as loss of normal grey-white matter differentiation are
appreciable but can be challenging to detect [1]. In the 12–
48 h after onset, the ischemic lesion becomes easily identifi-
able through a combination of swelling and a more rapid de-
cline in CT attenuation, such that the lesion appears darker
than normal white matter.
Preclinical experimental data suggest that this progressive
decline in CT attenuation represents worsening oedema, sec-
ondary to increases in both intra- and extra-cellular water.
Importantly, CT scanners are calibrated to the attenuation co-
efficient of water, meaning that attenuation values are quanti-
tative and ideal for measuring water uptake, even between
scanners. Depending on the degree of impairment in cerebral
blood flow, ischemic brain tissue suffers first cytotoxic (no net
water shift), then ionic and finally vasogenic oedema (with
greater degrees of net water uptake and swelling) [2, 3]. To
the best of our knowledge, the relationship between the non-
enhanced CT attenuation of ischemic brain and time has not
been precisely evaluated in humans.
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Up to 20% of ischemic strokes present with no known
time of symptom onset [4], and in one large series, 36% of
patients presented later than conventional eligibility time
limits for treatment [5]. Recent randomized trials of both
int ravenous thrombolysis [6 , 7] and mechanical
thrombectomy [8, 9] that selected patients with imaging ev-
idence of salvageable brain demonstrated treatment benefit
for patients who present late or with an unknown time of
symptom onset. However, these trials used imaging methods
(contrast-enhanced CT perfusion imaging or MRI) that are
not routinely available to all patients who present with
stroke, especially outside of major stroke centres in devel-
oped nations [10, 11]. Ideally, imaging selection in this con-
text would be as simple and widely applicable as possible so
that the broadest range of patients can be considered for
treatment without delay. For most patients worldwide who
present acutely with ischemic stroke, only non-enhanced CT
is likely to be available [10, 12].
The aims of our project were first to precisely quantify the
relationship between non-enhanced CT attenuation of ische-
mic brain lesions and time using well-defined stroke trial data
and second to test whether it is feasible to use only the CT
attenuation of ischemic lesions to accurately estimate time of
stroke onset for individual patients, the CT-Clock Tool.
Materials and methods
Study population
We used a subset of non-enhanced CT brain imaging from the
Third International Stroke Trial (IST-3) for this retrospective
feasibility analysis. IST-3 was a large (n = 3035) multi-centre
randomized controlled trial testing IV alteplase given within
6 h of stroke symptom onset versus open control [13]. Ethical
approval for IST-3 was granted by the Scotland A research
ethics committee and local ethics committees. Consent was
obtained for all patients. IST-3 was registered, Current
Controlled Trials ISRCTN25765518. Enrolment, data collec-
tion and results for IST-3 have been published [13, 14].
Briefly, adult patients with acute stroke of any severity
(assessed with the National Institutes of Health Stroke Scale,
NIHSS) and no upper age limit were eligible if stroke onset
time was clearly determined and treatment started within 6 h
of onset, and baseline brain imaging had excluded haemor-
rhage and structural stroke mimics.
Case selection
IST-3 imaging protocols and the process for visual scan as-
sessment by a central panel of experts have been described
[15]. For the present analysis, we sought a subgroup of pa-
tients with non-enhanced CT brain imaging acquired both
before treatment (baseline) and at follow-up (target follow-
up imaging window was 24–48 h after stroke symptom onset,
but this varied depending on clinical need and logistics; some
patients also had repeat follow-up imaging at different time
points), where at least one of these CT scans was thin slice (≤
2.5 mm); i.e. we measured attenuation only on thin-slice CT.
We used IST-3 central expert assessment of imaging to iden-
tify patients with obvious cerebral infarct at follow-up and to
classify scans as with/without leukoaraiosis; central scan reads
were not otherwise used in the present analysis. A neuroradi-
ologist, specializing in stroke imaging confirmed the presence
of a suitable ischemic lesion (clearly visible at follow-up and
deemed large enough to measure) and excluded any scans
with acute haemorrhage or degradation by imaging artefacts
such that lesion measurement was likely to be inaccurate. We
purposefully selected a comprehensive range of stroke-onset-
to-scan times from the available baseline and follow-up thin-
slice scans, as follows. For efficient spread of data points, we
aimed to include a maximum of the following: one scan for
each of the 360 min from 0 to 6 h (up to 360); one scan for
every 10 min window from 6 to 12 h (up to 36); one scan for
every 30 min window from 12 to 48 h (up to 72); one scan per
hour from days 3–7 (up to 120); and any scans from later time
points (i.e. up to a maximum of 588 scans). To help reach
these targets, we allowed baseline and follow-up scans from
the same patient to be included. If multiple scans were avail-
able for a given time point, we randomly selected only one.
Note, we did not intend this population to be representative of
routine clinical practice, we selected patients purely on the
basis of measurable ischemic lesions across the desired time
range in order to best quantify the CT attenuation-time rela-
tionship in ischemic stroke.
Measuring CT attenuation
After comparing different methods (see Supplementary
Material), we assessed CT attenuation changes of brain by
application of manual regions of interest (ROI) within ische-
mic lesions and contralateral normal brain mirrored on sagittal
midline. We thus derived an attenuation ratio for each scan as
ischemic brain/normal brain. We used Carestream PACS
(v11, Carestream Health Inc. Rochester, NY, USA) to view
all CTs using standard brain (centre 35 HU (Hounsfield
Units), width 70 HU) and/or narrowed ‘stroke’ (centre 25–
35 HU, width 30–40 HU) window settings, modified accord-
ing to user preference. Zoomed images were used to ensure
accurate placement of ROIs. The same stroke specialist neu-
roradiologist applied all ROIs using standard Carestream Oval
ROIMeasurement Tool and where possible placed a 100mm2
area round or ovoid ROI. We used smaller ROIs if required
(e.g. to avoid CSF spaces or focal calcification), but paired
measurements (e.g. between the ischemic lesion and normal
brain or between baseline and follow-up scans in the same
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patient) always used area matched ROIs (Fig. 1). If ischemic
lesions were not clearly visible on baseline scans, we used
follow-up imaging (viewed in parallel and co-registered using
the Carestream Automatic Registration tool) to guide ROI
placement. ROI placement was conducted blind to time from
stroke onset. When an ischemic lesion or lesions were visible,
we sampled the area with the lowest attenuation based on
visual assessment and ROI placement in as many candidate
areas as needed for each scan. We sampled both white matter
and grey matter with no preference. We recorded the lowest
mean attenuation within sampled ROIs and recorded the stan-
dard deviation (SD) of the attenuation measurement for each
ischemic lesion. Thus, we tested the precision of ROI
measurements of ischemic lesions and compared intra- and
inter-lesional measurement variance. We assessed relation-
ships between measurement precision of ischemic lesions,
time from stroke onset and background leukoaraiosis of brain
as potential confounders.
Testing reader reliability
We performed reader-reliability analyses using a random sub-
sample of our study population assessed separately. A second
reader, masked to all clinical and imaging data (including
previous ROI placement and results) and with limited prior
experience assessing ischemic stroke lesions on CT, was
Fig. 1 ROI placement within the same ischemic lesions on sequential
thin-slice CT scans for two different patients. Note: Upper panel: Two
sequential scan measurements from the same patient, left image at
175 min from stroke symptom onset, right image at 36 h from onset.
Lower panels: Three sequential scan measurements from the same pa-
tient, left image at 120 min, middle right image at 22 h, and lower right
image at 100 h from stroke onset
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trained using the same method described above and indepen-
dently scored 92 scans from 47 patients. We assessed inter-
rater agreement using intraclass correlation coefficient (ICC)
estimates (and their 95% confidence intervals, 95%CI) based
on a single rating, absolute agreement, two-way random ef-
fects model [16]. Second reader results were not otherwise
used.
Estimating time from stroke onset
We recorded the time and date of each CT scan from the
DICOM headers during ROI application. We then derived a
new variable elapsed time, as the difference between CT scan
time/date and recorded symptom onset time/date. Blind to all
attenuation measurements and all clinical data except elapsed
time, we divided our cohort into development (75%) and test
(25%) datasets. To ensure that elapsed time was represented
equally in both development and test datasets, we made minor
reallocations as necessary.
We used the development dataset to quantify the relation-
ship between change in ischemic lesion attenuation and time.
We plotted attenuation measures against elapsed time and
derived a best-fit logarithmic curve. We inverted the function
of this curve to create a formula for estimating time from
symptom-onset-to-scan (estimated time) using only attenua-
tionmeasures.We then applied our formula to each scan in the
test dataset to derive estimated time.
Validation of time estimation results
We compared estimated time and elapsed time in the test
dataset to quantify time estimation errors. We sought trends
for over- or under-estimation by subtracting estimated time
from elapsed time and assessed whether differences were pos-
itive (under-estimate) or negative (over-estimate). We used
absolute error for all validation assessment; i.e. we used the
magnitude differences between estimated and elapsed time by
converting negative time differences to positive so that all
values were greater than zero. We also derived absolute per-
centage error (absolute error/elapsed time × 100). We correlat-
ed absolute error with elapsed time and with attenuation mea-
sures. We selected subgroups of elapsed time, chosen to pres-
ent similar case numbers at clinically relevant cut points (i.e.
early, delayed, late and extremely late) and assessed the rela-
tionship between error and elapsed time. Finally, with elapsed
time as the reference standard and our attenuation measure-
ments as the index test, we performed a receiver operating
characteristic (ROC) curve analysis on the whole dataset to
test the theoretical discriminative ability of our CT Clock Tool
for determining intravenous alteplase eligibility according to
the European licensing limit of 4.5 h.
Statistical analyses
We present normally distributed data using mean (SD) and
non-parametric data as median (inter-quartile range, IQR).
For comparisons of normally distributed or dichotomous data,
we used independent sample t-tests. We used independent
sample Mann-Whitney U or Kruskal-Wallis tests for compar-
isons and Spearman’s Rho for correlations of non-
parametrically distributed data. We used Bland-Altman statis-
tics for assessing relationships between estimated time errors
and elapsed time [17]. For ROC analysis, we used Youden’s
index maximum value to identify the attenuation measure-
ment cut-off with the optimum balance of sensitivity and spec-
ificity and estimated area under the ROC curve.
We performed all analyses using IBM SPSS Statistics soft-
ware, versions 20 and 22 (IBM Corporation, Armonk, NY,
USA). We considered a p value < 0.05 significant.
Results
Study population
We selected and assessed 342 CT scans from 200 patients
(Fig. 2). Most patients (n = 105, 52.5%) contributed 2 scans,
77 patients (38.5%) contributed 1 scan, 17 patients (8.5%)
contributed 3 scans, and 1 patient (0.5%) contributed 4 scans.
Nearly half of all scans (n = 162, 47.4%) were acquired < 6 h
of stroke onset. Due to IST-3 design, few scans were available
6–12 h (n = 4, 1.2%) or 12–24 h (n = 14, 4.1%) after stroke
onset. Most remaining scans (n = 114, 33.3%) occurred 24–
Fig. 2 Flowchart for patient selection
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48 h from stroke onset, with 42 (12.3%) acquired between 3
and 7 days, and only 6 (1.8%) acquired beyond 7 days.
Among all scans, elapsed time ranged from 22 min to 865 h
(36 days), median 16.7 h, IQR 2.6 to 30.8 h.
Of the 200 patients included, 81 (40.5%) were male; the
median age was 83 years, IQR 74–87 years; baseline stroke
severity was moderate-severe with median NIHSS 17, IQR
11–21; and 93 patients (46.5%) were allocated to alteplase.
There were no significant differences between patients in the
development (n = 149) and test (n = 51) datasets, Table 1.
Measuring CT attenuation changes
From 342 CT scans assessed in total, the mean ischemic lesion
attenuation was 22.6 (SD 6.1) HU, compared with a mean
attenuation of 30.8 (SD 3.5) HU in contralateral normal brain.
Thus, the mean attenuation ratio for all scans was 0.73.
Precision was consistent for intra- and inter-lesional measure-
ment, the mean SD of individual lesions was 5.4 HU com-
pared to 6.1 HU for the entire group. The SD for individual
lesion measurements was not different for scans with versus
without background leukoaraiosis (p = 0.065), or for scans
performed before or after 4.5 h (p = 0.537), and there was no
correlation between lesion SD and elapsed time (p = 0.352), or
lesion SD and attenuation (p = 0.05). There were no signifi-
cant differences of these measured CT characteristics or
elapsed time between the development (n = 256) and test
(n = 86) datasets (Table 1).
Inter-rater agreement for the assessment of ischemic le-
sions, contralateral normal brain and attenuation ratio was
ICC (95%CI) = 0.89 (0.82–0.93), 0.55 (0.39–0.68) and 0.85
(0.75–0.91), respectively.
Estimating time from stroke onset
Figure 3 demonstrates the best-fit logarithmic curve (R2 =
0.768) derived by plotting attenuation ratio against elapsed
time for the 256 scans in the development dataset. A few
(n = 10) very early scans have an attenuation ratio greater than
1.0; i.e. CT attenuation in the affected brain is greater than the
CT attenuation of contralateral normal brain. Attenuation ratio
drops thereafter, and according to the best-fit curve measures
0.86, 0.82 and 0.79 at 3, 4.5 and 6 h elapsed time, respectively.
In the test dataset (n = 86), differences between estimated
and elapsed time were well balanced but with a slight trend
toward under-estimation (45 positive versus 41 negative dif-
ferences). Absolute error ranged from < 1 min to 247 h, with a
median of 315 min. The median absolute percentage error was
51% (IQR 25–72%). Absolute error was highly correlated
with elapsed time (r = 0.82, p < 0.000001) and with attenua-
tion measures (ischemic lesion attenuation r = −0.83, p <
0.000001, attenuation ratio r = − 0.86, p < 0.000001) such that
errors were smallest for scans with early or less
hypoattenuating ischemic lesions (Fig. 4 and Table 2). We
identified the following elapsed time subgroups in the test
dataset: early (≤ 3 h, n = 25), delayed (> 3 to 9 h, n = 17), late
(> 9 to 30 h, n = 20), extremely late (> 30 h, n = 24) (Table 2).
The median absolute error was 23 min for early, 106 min for
delayed, 1030 min for late and 1933 min for extremely late
scans (p value for difference < 0.0001). A similar trend was
observed for absolute percentage errors.
ROC analysis of all 342 scans suggested that an attenuation
ratio of 0.753 (Youden’s index = 0.80) would provide the op-
timum test sensitivity and specificity (96.5% and 83.1%, re-
spectively), for correctly classifying scans as before or after
the 4.5 h European licensing limit for intravenous alteplase.
Table 1 Comparison of development and test datasets
Variable Development dataset (75%) Test dataset (25%) p value for difference
Patient group comparisons (n = 200) n = 149 n = 51
Age (years) 84 (77–87) 81 (68–86) 0.065
Male sex 60 (40.3%) 21 (41.2%) 0.910
NIHSS 17 (11–21) 17 (10–22) 0.768
Allocated to alteplase 70 (47.0%) 23 (45.1%) 0.817
CT Scan characteristic comparisons (n = 342) n = 256 n = 86
Elapsed time (hours) 21.1 (2.6–30.7) 15.4 (2.5–32.2) 0.944
Ischemic lesion attenuation (HU) 22.6 (6.0) 22.5 (6.4) 0.842
SD of individual lesion measurements (HU) 5.3 (1.3) 5.5 (1.4) 0.208
Contralateral normal tissue attenuation (HU) 30.8 (3.4) 30.7 (3.5) 0.960
Attenuation ratio 0.73 (0.18) 0.73 (0.18) 0.805
Presence of leukoaraiosis† 132 (51.6%) 39 (46.4%) 0.416
Results are mean (standard deviation = SD), median (inter-quartile range) or n (percentage) as appropriate. 200 patients provided 342 CT brain scans for
analysis. Elapsed time = time from stroke symptom onset to scan. HU=Hounsfield Units. †Leukoaraiosis data missing for 2 test dataset scans
Neuroradiology
The area under the curve for ROC analysis was high at 0.955
(95% confidence interval 0.936–0.975) (Fig. 5).
Discussion
In this feasibility analysis, we provide evidence that it is
possible, with high accuracy and reasonable precision, to
estimate time from ischemic stroke onset using simple CT
brain attenuation measurements alone, particularly during
the early, most clinically relevant period. By closely map-
ping the attenuation changes of ischemic brain with time in
a well-defined stroke trial dataset, we have derived a for-
mula for understanding the time-attenuation relationship in
humans. We used the ratio of manually measured CT at-
tenuation in ischemic brain relative to contralateral normal
brain. Our CT Clock Tool can provide specific estimates of
stroke onset time for individual patients where ischemic
lesions are visible on NECT without the need for advanced
imaging or specialist software.
Agreement, error and accuracy of the CT Clock Tool
We found that time of stroke onset estimates were accurate
relative to true elapsed time, especially < 9 h from stroke
onset. The accuracy of our estimates was time dependent,
estimates for early scans (0–3 h) were more accurate (me-
dian error ± 23 min) than estimates for delayed scans (±
106 min for scans performed 3–9 h from stroke onset). The
difference between estimated time and elapsed time was
strongly positively correlated across the sampled time
range; the closer patients were to their stroke onset time,
the more accurate the prediction. Similarly, time estimation
errors were strongly negatively correlated with lesion at-
tenuation; i.e. the more obvious (darker) the lesion, the
greater the error. These associations are clinically
reassuring since methods to determine treatment eligibility
for patients with ischemic stroke are most needed in the
first hours after stroke onset, when lesions are not overtly
visible. The European licensing limit for intravenous
alteplase is 4.5 h and patients who wake up with stroke
symptoms are likely to be 6–9 h since last known to be
Table 2 Validation of estimated time results in the test dataset
Group Elapsed time
median (IQR), range
Estimated time
median (IQR), range
Over- and
under-estimates (n)
Absolute error
median (IQR)
Absolute percentage
error median (IQR)
All (n = 86) 924 (152–1932),
47–51,914
524 (146–3153),
32–37,069
41 over
45 under
315 (57–1486) 51 (25–72%)
≤ 3 h (n = 25) 110 (78–129),
47–171
122 (69–170),
32–483
14 over
11 under
23* (14–85) 29 (14–60%)
> 3 to 9 h (n = 17) 253 (217–305),
199–498
184 (148–278),
93–1032
3 over
14 under
106* (60–234) 38 (24–67%)
> 9 to 30 h (n = 20) 1567 (1452–1689),
873–1793
1477 (672–4467),
367–8778
10 over
10 under
1030* (597–2947) 65 (48–186%)
> 30 h (n = 24) 2950 (2209–5725),
1810–51,914
3661 (1994–6360),
701–37,070
14 over
10 under
1933* (705–3976) 52 (29–66%)
All results are in minutes, unless otherwise stated. IQR = interquartile range. Subgroups are based on elapsed time. *4 groups significantly different, p <
0.0001
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Fig. 3 Best-fit logarithmic function for attenuation ratio versus elapsed time in the development dataset (n = 256)
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well (i.e. before they went to sleep). Therefore, the clinical
challenge is often to determine which patients are within
and which are outside the 0–4.5 h treatment window for
alteplase. Minnerup and colleagues estimated that 11.5%
water uptake on non-enhanced CT (derived from attenua-
tion change) was the optimal cut off to classify patients
within the 4.5 h European licensing limit with high sensi-
tivity (91–99%) and specificity (78–91%), but used
contrast-enhanced CT perfusion imaging to first identify
ischemic lesions [18, 19]. On ROC analysis, the estimated
optimum test sensitivity and specificity of our CT Clock
Tool compared well with the Minnerup method at 97% and
83%, respectively. The true diagnostic accuracy of our CT
Clock Tool for identifying patients who are eligible for
alteplase will require further testing in a clinically repre-
sentative cohort and has the advantage of not requiring
perfusion imaging for guidance.
Precision and reliability of CT attenuation
measurements
Given the deliberately wide elapsed time range included in our
analysis, we expected and found greater variability of attenu-
ation measurements for ischemic brain tissue compared to
equivalent measurements of contralateral normal brain tissue
(at the group level SD 6.1 versus 3.5, respectively). We might
also have expected this variability in ischemic lesion measure-
ment to increase with elapsed time or with the natural progres-
sion of lesions, but we found no evidence of this. In other
words, the extent of variability was not affected by time from
stroke onset. Similarly, we found no difference in lesion mea-
surement variability between those with and those without
leukoaraiosis, a common coexistent finding among patients
with stroke. We also found measurement variance within in-
dividual ischemic lesions comparable to the variance between
different ischemic lesions.
Reader reliability for our method was excellent. We
found high levels of agreement for lesion measurement
between experienced and inexperienced readers (ICC
0.89). Interestingly, agreement was slightly less for atten-
uation measurement of the contralateral normal brain (ICC
0.55), but this did not significantly negatively impact
agreement for the calculated attenuation ratio (ICC 0.85)
thus estimated time is unlikely to be greatly different be-
tween readers.
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Such consistency and reliability of lesion measurement are
reassuring for the potential future clinical application of our
CT Clock Tool. On the other hand, we did observe greater
error for time estimation when scans were performed late ver-
sus early. This may reflect fewer attenuation measures in our
study at these later times but is also likely indicative of the
natural heterogeneity of lesion progression. Rocha and Jovin
describe fast and slow progressors among patients with prox-
imal large vessel obstruction being considered for
thrombectomy and suggest that variability in individual pa-
tient trajectories relates to differences in their collateral circu-
lation [20]. Those with good collateral supply are likely to
sustain viable brain tissue for longer and this concept is
backed by pre-clinical evidence [21]. In this context, it is
possible that some of the apparent discrepancies between
our CT Clock Tool and elapsed time reflect real CT measur-
able inter-patient differences, rather than error in our tech-
nique. We might be estimating time since infarct rather than
time since stroke symptom onset for patients with good col-
lateral supply, but this would require further testing. Kucinski
and colleagues demonstrated in a small group (25) of patients
with early ischemic stroke (< 5.4 h) that apparent diffusion
coefficient values (ADC, a component of diffusion weighted
MRI and often considered to represent infarct) of ischemic
lesions correlate with measurable non-enhanced CT attenua-
tion changes, albeit weakly [22]. In a small cohort of patients
(41) undergoing thrombectomy, Mokin and colleagues simi-
larly estimated that attenuation ratios of 0.94–0.96 most con-
sistently predicted tissue death [23]. These attenuation ratios
fit with the precipitous decline in attenuation demonstrated
during the first hour after stroke onset in our study (Fig. 3).
Ultimately, patient-specific lesion measurements are likely to
be more powerful predictors of brain tissue viability and thus
favourable treatment response than standard measures of
elapsed time in stroke and might be used to offer treatment
to patients who present late. An interesting and potentially
novel observation in our analysis was that the attenuation
of affected brain briefly increased in the very early stages
after ischemic stroke onset immediately prior to the de-
scribed rapid decline. This may reflect increased regional
blood volume, which is a recognized perfusion-imaging
feature of ischemia rather than infarct and likely a phys-
iological attempt to maximize nutrient delivery to the in-
jured but still viable brain tissue. Whether measuring this
increase in CT attenuation could provide a meaningful
assessment of brain tissue viability remains untested.
Associations between specific lesion measurements
thought to indicate tissue viability and improved clinical
outcome following treatment, even at extended elapsed
times, are beginning to emerge [6–9]. However, all of
these methods require the use of additional or advanced
imaging in the acute setting, which for the purpose of
broad clinical applicability we were keen to avoid.
Strengths and limitations of the present work and
future plans
We used the location of infarcts on follow-up imaging to
measure attenuation in very early ischemic lesions on baseline
imaging that were not yet visible to the human eye (generally
within the first hour) so that these too could be included in
order to achieve a more complete understanding of the time-
attenuation relationship. This information would not be avail-
able in a prospective analysis without the use of complemen-
tary advanced imaging to guide ROI placement. So while our
CT Clock Tool can be used without the need for MRI or
contrast-enhanced CT imaging (angiographic collateral scor-
ing or perfusion imaging) as others have done, we still need to
develop the most appropriate method for applying the tech-
nique when lesions are not easily seen. For example, deter-
mining when an ischemic lesion is likely to be present but not
visible versus not present. But for those with visible lesions,
we wanted to develop our method using manually placed
ROIs because this approach requires no specialist equipment
or software and is therefore readily replicable.
Developing a system that can make accurate estimates of
stroke onset time using only CT attenuation should ensure that
our CT Clock Tool can be widely applicable, even where
resources are limited, i.e. in any centre that can offer non-
enhanced CT to patients with symptoms of stroke. Our preci-
sion, accuracy and inter-reader reliability results support the
robustness of this method. However, we are also exploring
automated computational methods for the application of our
CT Clock Tool since assisted lesion detection may be the most
suitable method for applying our technique in many circum-
stances and may improve the reliability of lesion measure-
ments, but these assertions are currently unproven and such
methods are not yet widely available.
Our analysis includes a very broad range of elapsed times,
deliberately selected to be well-beyond recognized treatment
windows for ischemic stroke. This design was to ensure our
assessment of the relationship between attenuation and
elapsed time was comprehensive. Best-fit curves are likely
to benefit from more complete data, and our method also
needs to include patients who present very late to appropriate-
ly classify their scans. We acknowledge this broad time range
extends beyond the period for acute therapy. Similarly, we
selected non-conventional subgroups for elapsed time based
on the relatively small numbers available in our test dataset so
that our early, delayed, late and extremely late subgroups
were balanced while remaining clinically relevant. As de-
scribed above, up to 9 h from symptom onset is likely to be
most relevant for patients with wake-up stroke and for whom
our CT Clock Tool may be most helpful. We anticipate ex-
ploring more conventional elapsed timewindows (e.g. ≤ 3 and
≤ 4.5 h) as additional data are included in our model. We also
expect that given the strong relationship between estimation
Neuroradiology
error and elapsed time, that error is reduced for patients in the
critical early first half of our 3–9 h subgroup.
After the initial oedema that predominates the decrease in
CT attenuation of early brain ischemia and is utilized in our
study, more complex changes such as influx of protein-rich
fluids, petechial/capillary haemorrhage and compression of
tissues might act to conversely increase the CT attenuation
of affected brain at later time-points. Although we actively
excluded visible haemorrhage and sought scans with obvious
lesions at follow-up, these imperceptible processes could not
be completely excluded andmay partly explain greater error at
later time-points. Similarly, fogging of ischemic lesions on
brain CT is a transient phenomenon that can occur 2–
3 weeks after stroke onset where the attenuation of lesions
briefly appears to normalize before gliosis becomes readily
apparent [24, 25]. This pseudonormalization of ischemic le-
sions will not affect our measurements or time estimates dur-
ing the critical first hours after stroke onset but could have
affected our understanding of the time-attenuation relationship
at extremely delayed times. However, by only selecting cases
with obvious lesions on follow-up imaging, we should have
minimized this effect.
Potential sources of bias in our work are the use of only one
experienced scan reader for the primary analysis, use of mul-
tiple scans from the same patient, selection of patients based
on scan findings and time from stroke onset rather than repre-
sentative clinical features and not reaching our aspirational
target of 588 scans to cover the entire predefined time range
using IST-3 data alone. We plan to incorporate CT imaging
data from other sources, and we will continue to add new
cases to our development dataset until we meet the elapsed
time distribution targets described in methods.We also plan to
validate our technique in a larger representative dataset, to
provide human reader-reliability testing across a greater and
more representative range of reader abilities, and finally to
prospectively test the safety and applicability of our CT
Clock Tool in clinical populations. Thereby, we hope to max-
imize the real-world applicability of the data used to calculate
estimated time.
Conclusions
We have quantified the relationship between non-enhanced
CT attenuation of ischemic brain lesions and time and de-
veloped an easily replicable method for estimating time
from stroke symptom onset using only simple attenuation
measurements of visible lesions, the CT Clock Tool. Our
initial feasibility testing indicates reasonable precision, ac-
curacy and reliability of the method. With further develop-
ment and testing, our technique may offer a very quick and
widely applicable method for helping determine treatment
eligibility in ischemic stroke.
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